Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study
Interquartile range
Cladribine
DOI:
10.1016/j.msard.2022.103755
Publication Date:
2022-03-20T00:23:44Z
AUTHORS (8)
ABSTRACT
Cladribine tablets for adult patients with highly active relapsing multiple sclerosis (MS) have been available in Finland since 2018. Real-world data from different genetic and geographical backgrounds are needed to complement clinical trials.We investigated the use of cladribine a non-interventional cohort study, based on real-world nationwide Finnish MS registry. All eligible who had initiated treatment 2018-2020 were included. Descriptive analyses outcomes conducted using summary statistics. Time-dependent endpoints analyzed cumulated events analysis 1-Kaplan-Meier estimates curves. Subgroups separately according number previous disease-modifying therapies (DMTs) most common last preceding therapies.Data 179 analyzed. Median follow-up time was 19.0 months (interquartile range [IQR] 12.0-26.2). Of 134 followed at least 12 months, 112 (83.6%) remained relapse-free during follow-up. Mean annualized relapse rate (ARR) 1.0 (standard deviation [SD] 0.89) baseline, 0.1 (SD 0.30) Patients two or more DMTs shorter first (median 2.5 IQR 0.6-9.3) when compared 0-1 11.4 8.7-13.1) (p=0.013). After excluding switching fingolimod (n=33), statistically significant difference no longer observed between groups (p=0.252). Adverse (AEs) reported 30 (16.8%). The frequent AE headache (n=14, 7.8%). One patient (0.6%) died cardiac arrest. Discontinuation nine (5.0%).The mean ARR this similar what has trials. Approximately half used before tablets. These DMTs, mostly driven by early relapses fingolimod.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (23)
CITATIONS (31)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....